Ionis Pharmaceuticals IONS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 98.4%0.0pp | 98.3%-0.5pp | 98.8%-0.1pp | 98.9%+0.4pp | 98.5%+0.1pp | |
| Operating margin | -33.3%+7.2pp | -40.4%-11.7pp | -28.8%-0.5pp | -28.2%+37.6pp | -65.9%+1.5pp | |
| Net margin | -30.9%+9.5pp | -40.4%-13.9pp | -26.5%+1.9pp | -28.4%+35.4pp | -63.9%+0.5pp | |
| Returns | ||||||
| Return on equity | -67.6%+3.2pp | -70.8%-30.8pp | -40%+19.9pp | -59.9%+58.7pp | -118.6%-25.5pp | |
| Return on invested capital | -51%-26.8pp | -24.2%+8.2pp | -32.4%+8.3pp | -40.7%+137pp | -177.7%-62.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.1×+0.3× | 3.8×+1.0× | 2.8×-0.1× | 2.9×-6.8× | 9.7×+1.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.4×-3.6× | 5×+3.6× | 1.4×+0.2× | 1.3×+0.9× | 0.3×0.0× | |
| Per Share | ||||||
| Book value per share | $2.98-2.5% | $3.06-21.0% | $3.87+11.6% | $3.46+15.6% | $3.00-23.8% | |
| Valuation | ||||||
| Market capitalization | $12.4B-3.2% | $12.81B+22.9% | $10.43B+65.3% | $6.31B+31.5% | $4.8B-13.1% | |
| Price / sales | 11.7×-1.9× | 13.6×+2.8× | 10.8×+4.1× | 6.7×0.0× | 6.7×-1.1× | |
| Price / book | 25.2×-1.0× | 26.2×+9.3× | 16.9×+6.9× | 10×-0.1× | 10.1×+0.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ionis Pharmaceuticals's profit margins?
- Ionis Pharmaceuticals (IONS) runs a 98.4% gross margin and a -33.3% operating margin, with a -30.9% net margin.
- Where do Ionis Pharmaceuticals's ratios come from?
- Every ratio is computed from Ionis Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
